New York, March 31, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Hyperphosphatemia Treatment Global Market Report 2023" - https ...

DUBAI, United Arab Emirates, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Future Market Insights estimates that the Hyperphosphatemia Market will experience a rapid expansion between the years 2023 and 2033. By ...

Please provide your email address to receive an email when new articles are posted on . Phase 3 results from the PHREEDOM study demonstrated treatment with tenapanor safely and effectively decreased ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription The kidneys, in addition to removing toxins, ...

Nov. 4, 2002 — Lanthanum carbonate (Fosrenol) is safe and effective for the treatment of hemodialysis patients with hyperphosphatemia, according to two presentations on Nov. 2 at the American Society ...

Hyperphosphatemia Linked With Mortality in Septic AKI Hyperphosphatemia was associated with more than double the risk of death from any cause. Hyperphosphatemia may portend poor outcomes in septic ...

Tenapanor, a novel agent that has been submitted to the US Food and Drug Administration (FDA) for approval for the treatment of hyperphosphatemia in patients undergoing dialysis, moved a step closer ...

WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

Due to the lack of an appropriate dosage strength, Velphoro is not approved in pediatric patients 6 years to less than 9 years of age. The Food and Drug Administration (FDA) has expanded the approval ...

Credit: Ardelyx. Xphozah is a first-in-class oral medication designed to block sodium/hydrogen exchange 3 in the GI tract. Xphozah ® (tenapanor) is now available to reduce serum phosphorus in adults ...

Diabetes, COPD Raise Post-Kidney Transplant Readmission Rates High phosphate levels are associated with 3.3-fold increased odds of 28-day in-hospital mortality. Hyperphosphatemia predicts an increased ...